{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:09:40Z","timestamp":1791256180827,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41575-020-00406-0","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T06:13:01Z","timestamp":1610086381000},"page":"85-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["Nonalcoholic fatty liver disease: another leap forward"],"prefix":"10.1038","volume":"18","author":[{"given":"Manal F.","family":"Abdelmalek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"406_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73, 202\u2013209 (2020).","journal-title":"J. Hepatol."},{"key":"406_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389\u2013397 (2015).","journal-title":"Gastroenterology"},{"key":"406_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.06.025","author":"BA Davison","year":"2020","unstructured":"Davison, B. A. et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2020.06.025 (2020).","journal-title":"J. Hepatol."},{"key":"406_CR4","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/s41591-019-0660-7","volume":"25","author":"F Segovia-Miranda","year":"2019","unstructured":"Segovia-Miranda, F. et al. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat. Med. 25, 1885\u20131893 (2019).","journal-title":"Nat. Med."},{"key":"406_CR5","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184\u20132196 (2019).","journal-title":"Lancet"},{"key":"406_CR6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.004","author":"SA Harrison","year":"2020","unstructured":"Harrison, S. A. et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2020.08.004 (2020).","journal-title":"Gastroenterology"},{"key":"406_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/hep4.1107","volume":"1","author":"M Iruarrizaga-Lejarreta","year":"2017","unstructured":"Iruarrizaga-Lejarreta, M. et al. Role of Aramchol in steatohepatitis and fibrosis in mice. Hepatol. Commun. 1, 911\u2013927 (2017).","journal-title":"Hepatol. Commun."},{"key":"406_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome, P. N. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5, 362\u2013373 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"406_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhep.2020.04.034","volume":"73","author":"ME Rinella","year":"2020","unstructured":"Rinella, M. E. & Noureddin, M. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. J. Hepatol. 73, 9\u201311 (2020).","journal-title":"J. Hepatol."},{"key":"406_CR10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","volume":"55","author":"J Ludwig","year":"1980","unstructured":"Ludwig, J., Viggiano, T. R., McGill, D. B. & Oh, B. J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo. Clin. Proc. 55, 434\u2013438 (1980).","journal-title":"Mayo. Clin. Proc."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-020-00406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-020-00406-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-020-00406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:19:25Z","timestamp":1733941165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-020-00406-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["406"],"URL":"https:\/\/doi.org\/10.1038\/s41575-020-00406-0","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"8 January 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Research funding (paid to institution): Allergan, Intercept, Madrigal, Viking, Genfit, Gilead, Galactin, Novo-Nordisk, Novartis, NGM Bio, Bristol-Myers Squibb, Genentech, Celgene, Poxel, Durect, Enyo, Inventiva, Enanta, Target Pharma, Boerhinger-Ingelheim, Hanmi. Advisory\/consultancy: Allergan, Intercept, Madrigal, Novo-Nordisk, NGM Bio, Bristol-Myers Squibb, Inventiva, Boerhinger-Ingelheim, Promethera. Speaker\u2019s bureaus: Intercept, Clinical Care Options, Fishawack, Inc, Chronic Liver Disease Foundation, Medscape.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}